Abstract:Abstract Background: Gene fusions involving EWSR1 are involved in certain rare sarcomas and sarcoma-like tumors such as, for example, Ewing sarcoma, clear cell sarcoma, hyalinizing clear cell carcinoma, and clear cell odontogenic carcinoma. EWSR1-FLI1 fusions are found in Ewing sarcoma, while EWSR1-ATF1 and EWSR1-CREB are characteristic of clear cell sarcoma among others. Liquid biopsies involve obtaining tumor-derived materials through minimally invasive methods such as blood or other body fluid collection. Analysis of cell-free DNA (cfDNA) is an attractive method to identify gene fusions and monitor tumor recurrence and minimal residual disease (MRD). However, the structural complexity of oncogenic rearrangements poses challenges for the detection using plasma assays. We present a novel assay to monitor fusion positive tumor DNA in a busy oncology clinic. Methods and Patients: Patients with EWSR1 fusion positive sarcomas are identified through clinical RNA-based sequencing. Tumor DNA isolated from biopsy or surgical samples is sequenced to map the intronic breakpoint and customized primers spanning the breakpoint are designed for each patient. The breakpoint is subsequently confirmed through PCR. The product length of ~100bp accounts for the small shedding size of tumor cfDNA. A quantitative TaqMan assay is designed to confirm EWSR1 fusions. The limit of detection is determined by a dilution series of tumor DNA. cfDNA is extracted from blood samples of the patients at multiple timepoints, the tumor burden is quantified by TaqMan Assay and subsequently correlated with clinical findings from imaging studies such as tumor progression or remission. Results: We consented 10 patients with EWSR1 fusion positive tumors to participate in this study. Plasma samples were collected for 8, resulting in 26 total timepoints. Breakpoints were identified in 9 patients and confirmed with PCR on original tumor DNA. TaqMan assays were designed for 5 patients and showed correlation between the tumor burden detected in EWSR1-ATF1 copies in cfDNA extracted from patient blood and the therapeutic response to treatment found through imaging studies. One patient was followed over the period of 9 months, and a total of 5 plasma timepoints were collected. The patient started with a low number of EWSR1-ATF1 copies of <1ng/ul, while on a Iurbinectedin/irinotecan therapy and showed a mixed response in the CT scan. After withdrawing from that therapy and starting other therapy regimens, the EWSR1-ATF1 copies increase to 8ng/ul, correlating with tumor progression observed in CT scans. Conclusion: Our results suggest that ESWR1 fusions in sarcomas can serve as biomarkers to measure tumor burden. Our approach using an individually tailored cfDNA TaqMan assay could provide a valuable monitoring tool to inform clinicians about tumor progression or MRD. With these proof-of-principle findings we can now determine clinical validity and utility. Citation Format: Annie Li, Julia C. Thierauf, Bianca Gonda, Rashi Purohit, Stefan T. Kaluziak, Elizabeth Codd, Stacey N. Dybel, Edwin Choy, Gregory M. Cote, Jochen K. Lennerz, A John Iafrate. Customized liquid biopsy assay for monitoring EWSR1 fusions in sarcomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3657.

High-Throughput Hybridization Assay as First-Line Diagnostic Test for Sarcomas: Clinical Assessment in a Tertiary Referral Center

Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform

Abstract 2283: Validation & Application of Next-Generation Sequencing Panel YuanSu S for Gene Rearrangements/fusions Detection

Detection of sarcoma fusions by a next-generation sequencing based–ligation-dependent multiplex RT-PCR assay

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

The Impact of Next Generation Sequencing on Sarcoma Diagnosis.

Diagnostic Utility of Gene Fusion Panel to Detect Gene Fusions in Fresh and Formalin-Fixed, Paraffin-Embedded Cancer Specimens

The Utility of Integrative Genomic Profiling in Sarcoma Diagnosis and Treatment.

Investigating the Use of Circulating Tumor DNA for Sarcoma Management

Molecular profiling of gene fusions in soft tissue sarcomas by Ion AmpliSeqTM: a study of 35 cases

Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC

Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer

The application of next-generation sequencing-based molecular diagnostics in endometrial stromal sarcoma

Abstract 7408: Robust profiling of cancer-related gene fusions: Analytical validation of PANCARNA for multiple cancer types

Clinical Impact of Comprehensive Molecular Profiling in Adolescents and Young Adults with Sarcoma

mRNA Capture Sequencing and RT-qPCR for the Detection of Pathognomonic, Novel, and Secondary Fusion Transcripts in FFPE Tissue: A Sarcoma Showcase

SS18-SSX Antibody: A Useful Tool to Save Time and Reduce Costs in Synovial Sarcoma Diagnosis. Proposal of a Novel Diagnostic Algorithm

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Abstract 3657: Customized liquid biopsy assay for monitoring EWSR1 fusions in sarcomas

Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements